Interestingly, despite previous promising results in different cancer cohorts suggesting that BAF-deficient tumors might be more sensitive to ICI with improved clinical outcomes,26-29,47-49 our conflicting results among others22-24,30 enforced the hypothesis that wider genomic contexts than just BAF deficiency and cell’s ontogeny account for the efficacy of ICI. The gene discussed is BANF1; the disease is cancer.